Check official schedules to confirm the exact earnings date for CRISPR Therapeutics (CRSP) and assess the risk of capital lock-up if the release is delayed beyond 45 days.

AI-powered analysis for: Check official schedules to confirm the exact earnings date for CRISPR Therapeutics (CRSP) and assess the risk of capital lock-up if the release is delayed beyond 45 days.. Get detailed insights and real-time data on PolyPredict AI.

Explain the resolution rules for this CRSP earnings market in simple terms: what happens if the GAAP EPS is exactly $-1.26, or if the company only reports Non-GAAP figures?

AI-powered analysis for: Explain the resolution rules for this CRSP earnings market in simple terms: what happens if the GAAP EPS is exactly $-1.26, or if the company only reports Non-GAAP figures?. Get detailed insights and real-time data on PolyPredict AI.

Verify the reliability of SeekingAlpha as a data source: if CRSP's official document omits GAAP EPS, how quickly does SeekingAlpha typically publish this figure?

AI-powered analysis for: Verify the reliability of SeekingAlpha as a data source: if CRSP's official document omits GAAP EPS, how quickly does SeekingAlpha typically publish this figure?. Get detailed insights and real-time data on PolyPredict AI.

Search CRSP's historical earnings data over the past four quarters to calculate the actual frequency of the company beating consensus GAAP EPS estimates.

AI-powered analysis for: Search CRSP's historical earnings data over the past four quarters to calculate the actual frequency of the company beating consensus GAAP EPS estimates.. Get detailed insights and real-time data on PolyPredict AI.

Search for opposing bearish arguments and list the top 3 reasons why CRSP might report a wider loss (GAAP EPS below $-1.26) this quarter.

AI-powered analysis for: Search for opposing bearish arguments and list the top 3 reasons why CRSP might report a wider loss (GAAP EPS below $-1.26) this quarter.. Get detailed insights and real-time data on PolyPredict AI.

Compare the current Polymarket odds for a CRSP earnings beat with the implied probabilities from traditional US stock options markets to identify any pricing discrepancies.

AI-powered analysis for: Compare the current Polymarket odds for a CRSP earnings beat with the implied probabilities from traditional US stock options markets to identify any pricing discrepancies.. Get detailed insights and real-time data on PolyPredict AI.

Search Twitter and financial communities for recent expectations from prominent biotech analysts regarding CRSP's Q1 2026 earnings, and summarize their bullish/bearish sentiment.

AI-powered analysis for: Search Twitter and financial communities for recent expectations from prominent biotech analysts regarding CRSP's Q1 2026 earnings, and summarize their bullish/bearish sentiment.. Get detailed insights and real-time data on PolyPredict AI.

Given the current extremely low volume of $8.33, qualitatively assess the slippage risk for a $500 capital entry/exit in this illiquid market.

AI-powered analysis for: Given the current extremely low volume of $8.33, qualitatively assess the slippage risk for a $500 capital entry/exit in this illiquid market.. Get detailed insights and real-time data on PolyPredict AI.

Based on recent biotech news, predict if there are any potential catalysts, such as FDA approvals or milestone payments, that could cause odds volatility within 48 hours before the May 5 earnings.

AI-powered analysis for: Based on recent biotech news, predict if there are any potential catalysts, such as FDA approvals or milestone payments, that could cause odds volatility within 48 hours before the May 5 earnings.. Get detailed insights and real-time data on PolyPredict AI.

Analyze the impact of time decay (Theta) in this CRSP earnings market: if no news breaks before May 5, which side (Yes or No) benefits more?

AI-powered analysis for: Analyze the impact of time decay (Theta) in this CRSP earnings market: if no news breaks before May 5, which side (Yes or No) benefits more?. Get detailed insights and real-time data on PolyPredict AI.

Track whether well-known institutions (like Ark Invest) or insiders have recently disclosed changes in their CRSP stock positions, acting as a 'smart money' signal ahead of earnings.

AI-powered analysis for: Track whether well-known institutions (like Ark Invest) or insiders have recently disclosed changes in their CRSP stock positions, acting as a 'smart money' signal ahead of earnings.. Get detailed insights and real-time data on PolyPredict AI.

Analyze whether forecasting CRSP's quarterly EPS is purely guesswork, or if it is supported by predictable underlying financial logic such as Casgevy sales royalties.

AI-powered analysis for: Analyze whether forecasting CRSP's quarterly EPS is purely guesswork, or if it is supported by predictable underlying financial logic such as Casgevy sales royalties.. Get detailed insights and real-time data on PolyPredict AI.

Given the current wide bid-ask spread, suggest an optimal limit order price based on the fair value of the CRSP EPS > $-1.26 expectation that is easy to fill without losing edge.

AI-powered analysis for: Given the current wide bid-ask spread, suggest an optimal limit order price based on the fair value of the CRSP EPS > $-1.26 expectation that is easy to fill without losing edge.. Get detailed insights and real-time data on PolyPredict AI.

Provide a Delta Neutral calculator for users holding CRSP spot stock: if you hold 100 shares of CRSP, how many 'No' shares should you buy in this market to hedge against an earnings miss?

AI-powered analysis for: Provide a Delta Neutral calculator for users holding CRSP spot stock: if you hold 100 shares of CRSP, how many 'No' shares should you buy in this market to hedge against an earnings miss?. Get detailed insights and real-time data on PolyPredict AI.

Set a stop-loss red line: identify which core fundamental indicators or sudden bad news (e.g., unexpected clinical trial halts) should trigger an immediate stop-loss on a 'Yes' position.

AI-powered analysis for: Set a stop-loss red line: identify which core fundamental indicators or sudden bad news (e.g., unexpected clinical trial halts) should trigger an immediate stop-loss on a 'Yes' position.. Get detailed insights and real-time data on PolyPredict AI.

Calculate the opportunity cost of capital: considering the low liquidity and May 5 resolution date, assess if locking funds in this CRSP event is worth it compared to risk-free yields in DeFi protocols.

AI-powered analysis for: Calculate the opportunity cost of capital: considering the low liquidity and May 5 resolution date, assess if locking funds in this CRSP event is worth it compared to risk-free yields in DeFi protocols.. Get detailed insights and real-time data on PolyPredict AI.

Provide a 'Stink Bid' strategy guide for this deep, low-liquidity market, teaching users how to place extremely low bids to catch sudden panic selling right before earnings.

AI-powered analysis for: Provide a 'Stink Bid' strategy guide for this deep, low-liquidity market, teaching users how to place extremely low bids to catch sudden panic selling right before earnings.. Get detailed insights and real-time data on PolyPredict AI.

Recommend 3 other prediction markets highly correlated with CRSP (such as other gene-editing companies or biotech ETF performance) to help construct a diversified earnings trading portfolio.

AI-powered analysis for: Recommend 3 other prediction markets highly correlated with CRSP (such as other gene-editing companies or biotech ETF performance) to help construct a diversified earnings trading portfolio.. Get detailed insights and real-time data on PolyPredict AI.

Recommend 3 high-quality Twitter or YouTube accounts dedicated to analyzing CRSP's pipeline R&D progress or biotech earnings for in-depth insights.

AI-powered analysis for: Recommend 3 high-quality Twitter or YouTube accounts dedicated to analyzing CRSP's pipeline R&D progress or biotech earnings for in-depth insights.. Get detailed insights and real-time data on PolyPredict AI.

Synthesize CRSP's earnings estimates, liquidity, and resolution rules to generate a one-page trading plan, including entry rationale, target price, and contingency actions if rules are invalidated (e.g., delayed earnings).

AI-powered analysis for: Synthesize CRSP's earnings estimates, liquidity, and resolution rules to generate a one-page trading plan, including entry rationale, target price, and contingency actions if rules are invalidated (e.g., delayed earnings).. Get detailed insights and real-time data on PolyPredict AI.

Will CRISPR Therapeutics (CRSP) beat quarterly earnings?

Earnings|$346 Vol|

3 days 1 hrs

Will CRISPR Therapeutics (CRSP) beat quarterly earnings? - AI Mispricing Alert

AI Signal Dashboard

Last updated: 5 hours ago

Top Undervalued

+1¢

(Yes)

Will CRISPR Therapeutics (CRSP) beat quarterly earnings? AI analysis: • +1¢ undervalued • Live Prediction Market fair value & mispricing alerts.

Undervalued Options Insights:

Wall Street consensus estimates for CRISPR Therapeutics (CRSP) remain above the -$1.26 mark. Fundame...

🔓 Log in to see more

All Outcomes

Market Price

AI Fair Value

Value Edge

YesNo

54¢

46¢

55¢

45¢

+1¢

0¢

⚠️ Risk Warning: Live data may lag! Prices can shift instantly due to news or low liquidity. Before trading, use AI Chat for [Live Recalculate], [Check Liquidity], [Trollbox Radar], or review [Fair Value Logic] to verify.

Hedging

CRSP

This event directly corresponds to the earnings performance of CRISPR Therapeutics (CRSP). An earnings beat or miss (especially EPS) typically causes significant tradable price movements in the stock post-market or the following day, providing direct correlation and hedging value.

Movers

April 30, 2026 - May 1, 2026, the price of Option_'Yes' surged from 43.5c to 68.5c, before retracing to 54c on May 2. This was driven by traders increasingly betting on an earnings beat as the reporting date neared, pushing the price up, followed by profit-taking that led to a rational price correction. April 29, 2026 - April 30, 2026, the price of Option_'Yes' rebounded from 23.5c to 43.5c. This recovery occurred as market participants reassessed analyst consensus estimates ahead of the earnings release, realizing that fundamental data supports a higher probability of EPS exceeding -$1.26, thereby correcting earlier extreme pessimism. April 26, 2026 - April 28, 2026, the price of Option_'Yes' plunged from 48.5c to 25c. This sharp decline was likely driven by deep market pessimism regarding the company's ability to meet earnings expectations. Traders appeared to be heavily betting on another significant earnings miss following last quarter's disappointing results, expecting the EPS to fall below the -$1.26 threshold.